This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NICE Confirms AGNSS Positive Assessment That Eculizumab (Soliris®) Is A Very Effective Treatment For AHUS Patients And Produces Substantial Quality-Adjusted Life Year Gains Of A Magnitude Rarely Seen For A New Drug

Alexion Pharmaceuticals (Nasdaq:ALXN) is pleased that the National Institute for Health and Clinical Excellence (NICE) Evaluation Committee has acknowledged that eculizumab (Soliris ®) is a very effective treatment option for patients with aHUS, and that the use of eculizumab would be of significant value to patients with this life-threatening disorder who have no other treatment options.

In an Evaluation Consultation Document (ECD) released today, the NICE Evaluation Committee confirmed that currently available supportive care for patients with aHUS has limited impact on disease morbidity and mortality, but a substantial negative effect on a patient’s quality of life. Importantly, the Committee underscored that substantial restoration of health for a very long period is achieved with ongoing treatment with eculizumab. The Committee also concluded that eculizumab produced a substantial gain in quality-adjusted life years (QALY, a measure of the number of high-quality years of life gained) of a magnitude rarely seen for a new drug treatment – let alone one for an ultra-rare disorder.

Today’s very positive assessment by NICE of the clinical value of eculizumab for patients with aHUS aligns with the two prior positive recommendations from Government – AGNSS and NHS England. In addition, NICE confirmed today that the broad interim NHS England commissioning policy for eculizumab treatment of existing and new patients with aHUS will continue.

However, Alexion is concerned that nearly 3 years after Government commenced its evaluation, and more than 1 year after eculizumab was referred to NICE, the Committee was still unable to provide a formal recommendation whether eculizumab should be nationally commissioned. Additionally, NICE has now stated that it will seek further information from NHS England on what considerations relating to the management of its specialised commissioning budget it considers should be taken into account. NICE has also asked the company to provide additional information related to budget impact. NICE has not requested any additional clinical effectiveness information from Alexion.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs